Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longvida is a patented formulation of curcumin developed by Verdure Sciences in collaboration with neuroscientists at the University of California, Los Angeles (UCLA). It utilizes Solid Lipid Curcumin Particle (SLCP) technology, which encapsulates curcumin in a lipid matrix to significantly enhance its bioavailability and facilitate its passage across the blood-brain barrier. Curcumin, the primary bioactive component of turmeric (Curcuma longa), is known for its potent anti-inflammatory and antioxidant properties. Longvida is primarily targeted toward supporting cognitive function and joint health. Its mechanism of action involves the inhibition of pro-inflammatory cytokines, reduction of oxidative stress, and the potential prevention of amyloid-beta plaque aggregation, a hallmark of Alzheimer's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longvida.